Genentech submits BLA for trastuzumab-DM1 in advanced HER2-positive breast cancer

[News]

Genentech, a member of the Roche Group, today announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for trastuzumab-DM1 (T-DM1) in people with advanced HER2-positive breast cancer who have previously received multiple HER2-targeted medicines and chemotherapies.

More... (http://www.news-medical.net/news/20100707/Genentech-submits-BLA-for-trastuzumab-DM1-in-advanced-HER2-positive-breast-cancer.aspx)